Brain Targeted Drug Delivery (BTDD) is a cutting-edge approach that holds immense promise for revolutionizing the treatment of neurological disorders. The human brain's unique structure and protective barriers make delivering therapeutic agents to this organ a formidable challenge. However, BTDD employs innovative strategies to overcome these obstacles, offering targeted and efficient delivery of drugs to the brain. Nanoparticles play a pivotal role in BTDD, acting as carriers for drug transport across the blood-brain barrier (BBB). These nanoparticles can be engineered to enhance drug stability, solubility, and bioavailability, ensuring optimal delivery to specific brain regions. Additionally, functionalization of nanoparticles allows for targeted binding to receptors on brain cells, facilitating precise drug release.
Several neurological conditions, such as Alzheimer's disease, Parkinson's disease, and brain tumors, benefit from BTDD. Nanocarriers enable the delivery of therapeutic agents, including small molecules, proteins, and nucleic acids, directly to affected areas. This targeted approach minimizes systemic side effects and enhances the therapeutic efficacy of drugs. Furthermore, the development of smart drug delivery systems in BTDD integrates responsive elements that enable controlled drug release in response to specific physiological cues. This level of precision ensures that therapeutic agents are released at the right time and in the right amounts, optimizing treatment outcomes.
As BTDD continues to advance, interdisciplinary collaboration among researchers, pharmacologists, and nanotechnologists becomes increasingly crucial. The convergence of expertise in these fields is driving innovations in nanomedicine, paving the way for personalized and effective treatments for various neurological disorders.
The extensive research that we have undertaken has led to the development of a new drug specifically aimed at treating Alzheimer's disease using the liposomal drug Lipochrome. It has been widely…
Despite the fact that the global prevalence of neurologic illnesses is increasing, most medication molecules are still unable to reach the brain in therapeutic amounts. The blood-brain barrier is…
A growing body of evidence shows that Insulin, Insulin Receptor (IR) and IR signaling are involved in brain cognitive functions and their dysfunction is implicated in Alzheimer’s disease (AD)…
Participants can earn 1 CPD credit for each hour of attendance.
Oral and poster slots for original Brain Targeted Drug Delivery work, reviewed by the scientific committee.
Meet nanotechnologists, researchers, scientists and engineers from around the world across three days.
In-person and virtual registrations include an electronic copy of the abstract book.
Plenary lectures from leading voices shaping Brain Targeted Drug Delivery research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Brain Targeted Drug Delivery track is a dedicated stream within World Nano 2027 covering the latest research, innovation, and best practice in Brain Targeted Drug Delivery. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Nanotechnology researchers, scientists and engineers, educators and students with an interest in Brain Targeted Drug Delivery are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee.
Yes. World Nano 2027 is a hybrid conference — attend the Brain Targeted Drug Delivery track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 18–20, 2027· Hybrid · in-person & virtual
Attend without presenting.
